Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy
Xavier Puéchal, G. Pugnet, Benjamin Thoreau, Claire DE MOREUIL, S. Jouneau, Thomas Quéméneur, Gabriel Baron, P. Smets, Antoine Néel, Thomas Le Gallou, Nicolas Noël, Y. Uzunhan, Chloé Comarmond-Ortoli, G. Urbanski, Y. Benhamou, ALICE BEREZNE, Arsène Mekinian, Mohamed Amine Hamidou, Julien Campagne, Noémie Abisror, Pascal Cohen, Loı̈c Guillevin, Philippe Ravaud, Benjamin Terrier, French Vasculitis Study Group, Elisabeth DIOT, Jonathan London, Paul Legendre, Antoine Dossier, Nicolas SCHLEINITZ, Mikaël EBBO, Achille Aouba, Alexandre Nguyen, Divi Cornec, L. Sailler, Dominique Chauveau, P. Duffau, jean-francois Viallard, Carine Greib, Cécile Durant, Sabine Revuz, F. Maurier, Kim Heang LY, Nicolas Limal, Maxime Samson, Bernard Bonnotte, Eric Oziol, Renaud Felten, Nicolas Girszyn, S. Trad and 10 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance For participants with newly diagnosed or relapsing EGPA, rituximab was not superior to azathioprine for improving the duration of total remission during 28 months while taking prednisone at 7.5 mg/d or less.
ConclusionsAmong patients with IgA nephropathy, treatment with sibeprenlimab stabilized the eGFR slope over 24 months, a finding consistent with a reduced risk of kidney-function decline.
Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki and 22 more — New England Journal of Medicine
No mortality occurred at 5000 mg/kg, giving an LD50 above that limit; clinical signs, body weight, and rectal temperature showed no dose-related change.
N. N. Fadilah, S. R. Nur Endah, S. A. Sumiwi and 2 more — bioRxiv
BCI accuracy increased across training in four of five patients and was accompanied by patient-specific longitudinal changes in local spectral activity and functional connectivity.
C. Bousfiha, C. Gabot, D. Baili and 10 more — medRxiv
With the goal to develop better PDE4 inhibitors for the treatment of plaque psoriasis, two novel drug candidates were designed with computational studies, and observed to have better ADMET properties compared to Roflumilast.